Makena or compounded 17P?

摘要

I read with great interest the article in the July issue of P&T, entitled "Controversies in Practice," by Drs. Patel and Rumore regarding weekly injections of 17P for the prevention of pre-term birth.1 Lacking, sadly, was a return on investment (ROI) comparison as well as a summary of the facts surrounding this controversy. Had those been included, I am confident that the authors would have arrived at a very different conclusion. Absent that, they came up with a costly recommendation that accrues no proven additional health care benefit.